Meeting
2021 ASCO Annual Meeting
Open label phase II trial of cabozantinib (cabo) in patients with metastatic castrate resistant prostate cancer (mCRPC) and known amplifications or activating mutations in gene targets who have received prior anti-androgen therapy.
Authors
Jones T. Nauseef
NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY
Jones T. Nauseef , Sharon Singh , Angela Tan , Amie Patel , Brian D. Robinson , Francesca Khani , Charles G. Drake , Emerson A. Lim , Mark N. Stein , Elisabeth I. Heath , Himisha Beltran , Ana M. Molina , Bishoy Morris Faltas , Karla V. Ballman , Cora N. Sternberg , Scott T. Tagawa , David M. Nanus
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT04631744
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS5095)
DOI
10.1200/JCO.2021.39.15_suppl.TPS5095
Abstract #
TPS5095
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
A multicohort phase 2 trial of ADT, docetaxel plus nivolumab in patients with de novo metastatic hormone-sensitive prostate cancer enriched for inflamed tumors and DNA damage repair defects.
First Author: Xiao X. Wei
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY).
First Author: Yu-Wei Chen
Poster
2022 ASCO Annual Meeting
CaboMain: A phase 2 study of cabozantinib as a maintenance agent in patients with ultra-high risk pediatric solid tumors.
First Author: Nilay Shah
Poster
2014 ASCO Annual Meeting
Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial of the PMH, Chicago, and California Phase II Consortia.
First Author: Michelle Wilson